• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MYQ 5.56% 28.5¢

MYFIZIQ LIMITED - Corporate Spotlight

MyFiziq has developed and patented a proprietary dimensioning technology that enables its... MyFiziq has developed and patented a proprietary dimensioning technology that enables its users to check, track, and assess their dimensions using only a smartphone privately and accurately.More

Corporate Spotlight

MyFiziq has developed and patented a proprietary dimensioning technology that enables its users to check, track, and assess their dimensions using only a smartphone privately and accurately.
View the full Corporate Spotlight arrow Created with Sketch.

Investor Updates with MyFiziq CEO, July

VIDEOS

arrow-down-2 Created with Sketch.


Investor Updates with Vlado Bosanac, ED and CEO MyFiziq - July 2020



Investor Updates with Vlado Bosanac, CEO MyFiziq - June 2020


MYQ TO EXPAND INTO CANCER CARE SPACE

arrow-down-2 Created with Sketch.

22nd June 2020 - The Market Herald


  • Scanning tech developer MyFiziq (MYQ) is set to expand into the world of cancer care
  • The ASX-lister is teaming up with oncology researcher, Dr Kate Barrett, to bring its body composition technology into the cancer treatment sphere
  • MyFiziq wants to create a module which can accurately measure body surface area (BSA) from a mobile phone 
  • If successful, a handheld, mobile-based BSA measurement tool can replace "outdated" manual calculations, which are far less accurate
  • BSA calculations can help clinicians provide customised treatment doses to patients, improving a drug's efficacy while reducing its toxicity
  • Now that MYQ has locked in on a prospective target market, it's begun developing a BSA measurement module
  • The company plans to begin testing this technology on real subjects in the next 60 days
  • Despite the news, MYQ shares have slumped 8.77 per cent to trade for 26 cents each in midday trade

Scanning tech developer MyFiziq (MYQ) is set to expand into the world of cancer care.

The ASX-lister is teaming up with oncology researcher, Dr Kate Barrett, to bring its body composition technology into the cancer treatment sphere.


Under this new expansion, MYQ will extend the capabilities of its scanning technology so it can be used to calculate body surface area (BSA) and other critical measurements.


"Improving the analytics of body measurements ... allows for an opportunity to optimize ‘virtually deployable anywhere’ technology to further understand physiological changes for that individual cancer patient, and ultimately the predictive and preventative power in therapeutics."

Dr Kate Barrett

What is BSA?

When prescribing medications to treat cancers, oncologists will often use body surface area calculations. 

This BSA calculation can figure out a patient's total surface area, which can be used to measure drug dosage. On the other hand, the BMI index measurement can determine whether someone's weight lies within a healthy range.

In a clinical setting, knowing a patient's BSA ensures the right treatment dose is prescribed, customised to their measurements. Accordingly, a dosage prescribed using BSA can improve a treatment's efficacy and reduce its toxicity.

However, calculating a patient's BSA accurately can be tricky.


Making the calculations

When it comes to BSA measurements, 3D scanning technologies have been deemed the most accurate.

The kicker? This kind of equipment can be costly, inconvenient and inaccessible in a clinical setting.

This is where MYQ comes in; its mission is to create a "cost-effective, convenient and personalized mobile device measurement capturing system" for the cancer care space.


If successful, a handheld, mobile-based BSA measurement tool can replace "outdated" manual calculations, which are far less accurate.


In fact, MyFiziq says the two most widely used manual formulas for determining BSA — known as Mosteller and DuBios — have an approximate error rate of 10 per cent. Additionally, these can carry a hefty deviation weighting of up to 35 per cent.


"The MyFiziq technology has the potential to change the way these calculations are implemented and furthermore bring a higher level of efficiency and safety in patient care."

MyFiziq market announcment, June 22

If MYQ finds success in this space, it could also expand into other areas where BSA measurements are critical. These include the cancer chemotherapy, transplantology, burn treatment and toxicology sectors.

MYQ's exposure to the health sector


While today's announcement marks the beginning of MYQ's foray into cancer care, it isn't the company's first venture into the healthcare sector.


MyFiziq is working closely with the fitness app, Bearn, to provide body tracking technology to the platform's users. More recently, MYQ partnered with NuraLogix to create a "never before seen"health app that can determine health information from a 30-second selfie.


In fact, it's MYQ's experience in creating digital compositions for healthcare that Chief Scientific Officer Dr Amar El-Sallam says sets it up for success.


“MyFiziq has collected one of the world’s largest human shape and medical body composition image libraries, with over 7000 human subjects from Australia and around the world. I have used this deep and diverse data set to train and validate our accuracy in readiness for external review," she explained.


Now that MYQ has locked in on a prospective target market, it's begun developing a BSA measurement module. There's also an extension of this which will be specific to the oncology department.

As a result, MyFiziq plans to begin testing this technology on real subjects in the next 60 days.


"The ability to make accurate and consistent evaluations through a handheld device will simplify the process on several levels in clinical and preventative medicine," says Dr Kate Barrett.


"Not only will it be easier to track and document BSA calculations for chemotherapies, pain medications, and other supportive drugs across the healthcare team, it will enable an improved visualization of individual trends such that we can prevent and support concerning changes readily," Kate continued.


Despite the news, MYQ shares have dipped on the ASX in midday trade. Stock has slumped 8.77 per cent to trade for 26 cents each at 12:26 pm AEST.


22nd June 2020 - The Market Herald

MYQ SIGNS MOU WITH NURALOGIX CORP

arrow-down-2 Created with Sketch.

MyFiziq signs Memorandum of Understanding with NuraLogix Corporation

ASX Release 15th June


Highlights

  • MyFiziq - NuraLogix integration to be tested in Brazil and China.

  • Never before available digital health and chronic illness assessment.

  • Facial and Body Scan in under 2 minutes.

  • Combining Patented Technologies in a unique offering.

  • COVID-19 symptoms-based tool which predicts likelihood of infection.


MyFiziq Limited (ASX: MYQ) is pleased to update shareholders with the signing of a Memorandum of Understanding (MoU) with Canadian based NuraLogix Corporation.


NuraLogix has developed patented technology which utilizes a video camera like that found on a smartphone to take a 30 second selfie video of your face and determine a wide range of physiological and health related parameters such as: heart rate, heart rate variability, blood pressure, stress, cardiovascular disease risks and much more. The underlying technology is called Transdermal Optical Imaging (TOITM) and uses the video camera to extract blood flow information from your face. This information is then processed by advanced machine learning algorithms residing on NuraLogix’s cloud based Affective AI (Artificial Intelligence) Engine called DeepAffexTM.


The MyFiziq image dimensioning capabilities will be combined with DeepAffex and Transdermal Optical Imaging, to form a never before seen total health screen from a mobile phone. The combined digital capabilities of the two companies due to their patent coverage along with the unique offering is a one of a kind solution, that can be used whether you are 18 or 85 years of age.


The non-invasive combined solution delivers complete privacy to the consumer, which culminates in the individual being given assessments on multiple levels, such as;

  • Blood pressure. Stress levels.
  • Heart rate.
  • Heart rate variability. Irregular heartbeat. Respiratory rates. Emotion.
  • Total body fat.
  • Waist to height ratio.
  • Waist to hip ratio. Cardiovascular disease risk. 
  • Type 2 diabetes risk, and Stroke risk.

The resulting captures and data are allowing an individual the opportunity to understand their personal exposure to these diseases that form up to 70% of deaths globally each year, not including the current pandemic All publications and research have been published on NuraLogix website. 


Furthermore, we will allow an option for an individual to engage in an in-app COVID-19 symptoms analysis, which has been developed and tested, by NuraLogix in collaboration with St. Michael’s Hospital, University of Toronto, and Zhongda Hospital in China to produce an AI based model which was trained and tested on the symptom’s profiles of COVID-19 patients. 


The model predicts the likelihood of someone having COVID-19versusseasonalfluorcold. NuraLogixhasbeenpublishedpreviouslyforitsworkindetermining health parameters via a mobile device in world leading publications such as The American Heart Association - Circulation: Cardiovascular Imaging. The doctors and clinicians that collaborated with NuraLogix in concluding the COVID-19 study have determined the outcome to be so significant, the results are being presented for publication.


Anura COVID Sample Screens

page2image1216073280


Organizations around the world have been exploring the potential combination of thermal imaging cameras with drone technology to scan crowds as a measure in the fight against current and future pandemics. We are looking to be less invasive from a personal perspective, allowing individuals the choice to screen themselves at home or work when they feel they may have been exposed and are showing any of the known symptoms.


Under the terms of the MOU, the parties have agreed to develop the application in a demonstratable mobile application (Demo App) combining their technologies to be used to evaluate potential for a full commercial version of the application over the next 90 day period (Term). At the end of the Term, should both parties consider the response of potential customers to the Demo App to be promising enough for further pursuit, they shall then negotiate a formal commercial agreement to specify terms including, but not limited to, pricing, revenue sharing, intellectual property, development work and marketing.


MyFiziq and NuraLogix intend to integrate the patented solutions to expand the capabilities of their capture suite for a potential global market. Initially, we will only offer the Demo App to The Serfaty Clinic in Brazil and WeSure/WeFit in Mainland China. Upon a successful outcome, we will look to take the offering to a broader global audience. MyFiziq has undertaken the entirety of the integration to expediate the process. We envisage the completion of the build in readiness for hand over to be in the next 60 days.


Vlado Bosanac, Chief Executive Officer of MyFiziq, said:

“This is an extremely exciting partnership for the companies. Bringing our technologies together will not only create a one of a kind solution, furthermore it will be unrivalled. Our offerings in a standalone environment have a deep patent suite.


When combining the company solutions, we form not only a unique offering, but one that enhances both companies’ ability to be the dominant player in digital health and convenience. The solutions form an easy to use, comprehensive review of an individual, accurately, privately, and conveniently from their mobile phone. We have left the commercial terms aside at this point in time, as the initial targets are existing clients of MyFiziq and we will determine the commercial aspects of consumer use in conjunction with them, upon the successful evaluation by the partners.


As mentioned, we will initially be offering the solution to only 2 of our partners, being The Serfaty Clinic in Brazil, and WeSure in Mainland China. These organisations have a combined population in their countries of 1,600,000,000 billion. With Brazil rapidly becoming the world’s 2nd most effected country by the current pandemic, we initiated this partnership specifically for Dr Serfaty in line with our earlier ASX release outlining the preliminary agreement targeting COVID-19 and the inherent risk Brazil was facing. As we explored and understood the ease of use when combining these world class technologies, we then felt it was a potential suitor for the solution we have been working hard on for WeSure / WeFit in the WeChat platform.”


Marzio Pozzuoli, Chief Executive Officer of NuraLogix, said:

“We’re excited about working with MyFiziq and combining our two technologies to produce a unique solution to help improve the health and wellness of people everywhere especially during this time of the pandemic.

About NuraLogix


NuraLogix is a pioneer of Affective Artificial Intelligence (AI) which is the combination of affective computing and artificial intelligence. The company has developed the world’s first cloud based Affective AI Engine, DeepAffexTM, which utilizes the company’s proprietary facial imaging technology, Transdermal Optical Imaging(TOITM), to predict a wide array of human physiological and psychological affects using nothing more than the video camera found on any smartphone. Using this technology, the company developed the world's first smartphone app, AnuraTM, that can inform you about your general health and wellness in 30 seconds.


The company's objective is to use its technology to improve the lives of people everywhere. For mor information please visit: 

Staying at home during the current pandemic can be both physically and mentally exhausting. Now more than ever, it is important to be aware of, and monitor your physical and mental wellness using these combined solutions. With these technologies, you can measure many health indicators for you and your family from the convenience of your home, using just your smartphone.”


About MyFiziq:

MyFiziq has developed and patented a proprietary dimensioning technology that enables its users to check, track, and assess their dimension using only a smartphone privately and accurately.


Our goal is to assist our partners by empowering their consumers with this capability. This in return gives our partners the ability to assess, assist, and communicate outcomes with their consumers when navigating day to day life. Whether this is a personal journey to better health, understanding the risk associated with their physical condition, tracking the changes they are experiencing through training, dieting, or under medical regimes. or simply wanting to be correctly sized for a garment when shopping online. The MyFiziq technology delivers this seamlessly, privately, and cost-effectively in under one minute.


Our partner benefits from our (SAAS) Software as a service pricing solution, that reduces with scale. Integration is made easy with the MyFiziq modular system, based on multiple (SDK’s) software development kits, allowing a partner to select the functions, measurements, and displays to suit their individual needs.


MyFiziq has developed this capability by leveraging the power of Computer Vision, Machine Learning, and patented algorithms, to process these images on secure, enterprise-level infrastructure, delivering an end-to- end experience that is unrivaled in the industry. MyFiziq simplifies the collection of measurements and removes the human error present in traditional methods.


Read the full ASX Release Here

EVOLT APP AVAILABLE ON APP STORE

arrow-down-2 Created with Sketch.

Evolt Active Application with MyFiziq integration now available on Apple App Store

ASX Release 9th June 2020


Highlights

  • The MyFiziq - Evolt integration live on App Store.

  • Evolt is well intrenched in Fitness, Wellness, Gyms, Clinics and Workplaces.

  • Evolt has over 500,000 active users with a scan costing $30-$50 per scan.

  • Evolt is an FDA approved medical grade device.

  • Evolt currently has over 500 active locations and new orders for more than 4,000 Evolt units worldwide.


MyFiziq Limited (ASX: MYQ) is pleased to update shareholders with the release of the Evolt360 application (Evolt), which is now available in the Apple App store.


As previously outlined, Evolt is a device/machine-based intelligent body scanning technology purchased and supported by health, fitness, and wellness companies including but not limited to; F45, Anytime Fitness, HCF, and KPMG. These companies and more are looking to provide greater insight into the health of their members and employees. The scans performed by the existing Evolt technology are made available to consumers for between $30 - $50 per scan depending on the type of scan performed and level of membership. Evolt has today released the much awaited Evolt Active application with in app body scanning using the MyFiziq technology.


The MyFiziq technology is intended to extend the Evolt reach into the hands of their 500,000 consumers at home. With the new integration, customers of Evolt will be able to download access to the MyFiziq technology, via the Evolt Active app, which is available on the Apple App Store. The Evolt Active application with the MyFiziq in-app scanning capability is being released on iOS initially, with Android to follow.


In addition to the body tracking capabilities, Evolt will be embedding its biometric data into the machine learning data with MyFiziq within the application. Delivering a broader data set than has been made available in any application of its kind to date.

Evolt has developed a unique end-to-end solution that tracks detailed changes in the quality of the activity, body composition and nutrition as well as sophisticated data analytics for its user’s body changes, and now the added functionality of tracking circumference change as an additional data set. Evolt is inspiring and educating its users with real-time data to drive and assist in the delivery of personal goals.


In just a few short years, Evolt has become a global player, securing contracts across multiple verticals, from health insurers, health, and fitness retailers to government bodies and some of the world’s largest gym chains.


Vlado Bosanac, Chief Executive Officer of MyFiziq, said:

“The launch of Evolt has been much awaited both by MyFiziq and our shareholders. Evolt has committed to targeting an initial 100,000 active users onto the joint offering in the first 12 months and MyFiziq will receive $2.99 per month per user. This will mark the release of our second consumer application. If the initial target user numbers are achieved, it would see the Company meet an initial break-even position, based on current monthly burn.


The application has been through rigorous testing in readiness for this launch. I am pleased to say the application is performing well on all fronts. The look and feel of the application is a credit to both teams. We are looking forward to supporting Evolt with its launch, users, downloads, and usage.


As Evolt has been granted an FDA medical device approval, we believe this will bring a great deal of interest to both companies as we co-promote this unique and comprehensive capability to multiple business verticals, both current and new.


The FDA medical device approval held by Evolt is of particular benefit to both companies as we share a common interest in distributing the solution to governments, medical organisations, and insurers. The FDA approval brings validity to the device and its functionality is often required in such organisations, when looking to use the device as part of a decision-making process rather than a monitoring device. ”


About Evolt

Evolt is a technology driven health and wellness company that is powering connected and digital health. Evolt has developed an end-to-end solution that tracks detailed changes in the quality of activity, body composition and nutrition as well as sophisticated data analytics for an individual’s body composition changes.


Evolt is at the forefront of technology and use an evidence-based approach to its development and practical use. We have our own Research and Development Team consisting of highly qualified professionals in the field of exercise science, body composition and nutrition.


ASX Release 9th June 2020

ABOUT MYFIZIQ

arrow-down-2 Created with Sketch.

ABOUT US

Visit myfiziq website 


MyFiziq has developed and patented a proprietary dimensioning technology that enables its users to check, track, and assess their dimensions using only a smartphone privately and accurately. 


Our goal is to assist our partners by empowering their consumers with this capability. This in return gives our partners the ability to assess, assist, and communicate outcomes with their consumers when navigating day to day life. Whether this is a personal journey to better health, understanding the risk associated with their physical condition, tracking the changes they are experiencing through training, dieting, or under medical regimes. or simply wanting to be correctly sized for a garment when shopping online. The MyFiziq technology delivers this seamlessly, privately, and cost-effectively in under one minute. 


Our partner benefits from our (SAAS) Software as a service pricing solution, that reduces with scale. Integration is made easy with the MyFiziq modular system, based on multiple (SDK’s) software development kits, allowing a partner to select the functions, measurements, and displays to suit their individual needs. 


MyFiziq has developed this capability by leveraging the power of Computer Vision, Machine Learning, and patented algorithms, to process these images on secure, enterprise-level infrastructure, delivering an end-to-end experience that is unrivaled in the industry. MyFiziq simplifies the collection of measurements and removes the human error present in traditional methods.


Visit myfiziq website

(20min delay)
Last
28.5¢
Change
0.015(5.56%)
Mkt cap ! $32.60M
Open High Low Value Volume
28.5¢ 28.5¢ 27.5¢ $96.82K 344.2K

Buyers (Bids)

No. Vol. Price($)
1 10000 28.0¢
 

Sellers (Offers)

Price($) Vol. No.
28.5¢ 19262 3
View Market Depth
Last trade - 15.35pm 14/07/2020 (20 minute delay) ?
(live)
Last
28.5¢
  Change
0.015 ( 5.56 %)
Open High Low Volume
28.5¢ 28.5¢ 27.5¢ 141726
Last updated 15.35pm 14/07/2020 (live) ?
MYQ (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.